Infectious Diseases Clinic, Department of Health Sciences, University of Genova and Ospedale Policlinico San Martino-IRCCS per l'Oncologia, Genoa, Italy.
Centro de Investigación Biomédica en Red-Enfermedades Respiratorias (CIBERES), Barcelona, Spain; Clinical Research & Epidemiology in Pneumonia and Sepsis (CRIPS), Vall d'Hebron Institute of Research, Barcelona, Spain.
Int J Antimicrob Agents. 2020 Dec;56(6):106184. doi: 10.1016/j.ijantimicag.2020.106184. Epub 2020 Oct 9.
We investigated the impact of appropriate versus inappropriate initial antimicrobial therapy on the clinical outcomes of patients with severe bacterial infections as part of a systematic review and meta-analyses assessing the impact of delay in appropriate antimicrobial therapy. Literature searches of MEDLINE and Embase, conducted on 24 July 2018, identified studies published after 2007 reporting the impact of delay in appropriate antibiotic therapy for hospitalised adult patients with bacterial infections. Results were statistically pooled for outcomes including mortality, hospital length of stay (LOS) and treatment failure. Subgroup analyses were explored by site of infection where data permitted. Inclusion criteria were met by 145 studies, of which 114 reported data on the impact of appropriate versus inappropriate initial therapy. In the pooled analysis, rates of mortality were significantly in favour of appropriate therapy [odds ratio (OR) = 0.44, 95% CI 0.38-0.50]. Across eight studies, LOS was shorter with appropriate therapy compared with inappropriate therapy [mean difference (MD) -2.54 days (95% CI -5.30 to 0.23)], but not significantly so. The incidence of treatment failure was significantly lower in patients who received appropriate therapy compared with patients who received inappropriate therapy (six studies: OR = 0.33, 95% CI 0.16-0.66) as was mean hospital costs (four studies: MD -7.38 thousand US$ or Euros, 95% CI -14.14 to -0.62). Initiation of appropriate versus inappropriate antibiotics can reduce mortality, reduce treatment failure and decrease LOS, highlighting the importance of broad‑spectrum empirical therapy and rapid diagnostics for early identification of the causative pathogen. [Study registration: PROSPERO: CRD42018104669].
我们研究了适当与不适当初始抗菌治疗对严重细菌感染患者临床结局的影响,这是系统评价和荟萃分析的一部分,旨在评估适当抗菌治疗延迟的影响。2018 年 7 月 24 日,我们对 MEDLINE 和 Embase 进行了文献检索,确定了 2007 年后发表的报告住院成人细菌感染患者适当抗生素治疗延迟影响的研究。对包括死亡率、住院时间(LOS)和治疗失败在内的结局进行了统计学汇总。在数据允许的情况下,进行了感染部位的亚组分析。有 145 项研究符合纳入标准,其中 114 项报告了适当与不适当初始治疗影响的数据。汇总分析显示,适当治疗组的死亡率显著降低[比值比(OR)=0.44,95%置信区间(CI)0.38-0.50]。在八项研究中,适当治疗组的 LOS 比不适当治疗组更短[平均差(MD)-2.54 天(95%CI-5.30 至 0.23)],但差异无统计学意义。与接受不适当治疗的患者相比,接受适当治疗的患者治疗失败的发生率显著降低(六项研究:OR=0.33,95%CI 0.16-0.66),平均住院费用也显著降低(四项研究:MD-7.38 千美元或欧元,95%CI-14.14 至-0.62)。与不适当抗生素相比,使用适当抗生素可以降低死亡率、降低治疗失败率并缩短 LOS,这突出表明了广谱经验性治疗和快速诊断对于早期确定病原体的重要性。[研究注册:PROSPERO:CRD42018104669]。